⚙

Pathophysiology

7

Atherosclerotic renal artery stenosis

Atherosclerotic plaque narrows the renal artery lumen, usually as part of a diffuse atherosclerotic process. This stenosis reduces downstream renal perfusion and is the most common adult mechanism for renovascular hypertension and ischemic kidney injury.

endothelial cell link vascular smooth muscle cell link

extracellular matrix organization link ⚠ ABNORMAL

Downstream

Renal hypoperfusion and RAAS activation Luminal narrowing lowers perfusion pressure in the post-stenotic kidney.

Show evidence (2 references)

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Atherosclerotic renovascular disease is the most frequent cause of renovascular hypertension and its prevalence increases with age and in specific subset of patients, such as those with end-stage chronic kidney disease, heart failure, and coronary artery disease."

This review identifies atherosclerotic renovascular disease as the leading adult cause and places it in high-risk vascular comorbidity contexts.

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Atherosclerotic renovascular disease is usually part of a more diffuse atherosclerotic process and requires a combination therapy including antihypertensive, antiplatelet and lipid-lowering agents, as well as optimization of antidiabetic treatment, if needed."

This supports systemic atherosclerotic disease and cardiometabolic risk management as central etiologic and treatment context.

Renal fibromuscular dysplasia arteriopathy

Fibromuscular dysplasia is a nonatherosclerotic renal artery arteriopathy in which mature vessel-wall remodeling and medial structural disorganization narrow renal arterial flow and produce renovascular hypertension.

vascular smooth muscle cell link

blood vessel remodeling link ⚠ ABNORMAL collagen fibril organization link ⚠ ABNORMAL

Downstream

Renal hypoperfusion and RAAS activation Fibromuscular dysplasia narrows renal arterial inflow and lowers downstream perfusion pressure.

Show evidence (3 references)

DOI:10.1161/ATVBAHA.119.313885 SUPPORT Human Clinical

"We studied 4 independent probands with the COL5A1 pathogenic variant c.1540G>A, p.(Gly514Ser) who presented with arterial aneurysms, dissections, tortuosity, and mFMD affecting multiple arteries. Arterial medial fibroplasia and smooth muscle cell disorganization were confirmed histologically."

This supports an FMD-spectrum structural arteriopathy with mature arterial wall remodeling and smooth muscle disorganization.

DOI:10.1161/hypertensionaha.121.17004 SUPPORT Human Clinical

"Over 95% of cases of renovascular hypertension are due either to atherosclerosis of the main renal artery trunks or to fibromuscular dysplasia."

This establishes the two dominant etiologic classes for renovascular renal artery obstruction.

PMID:15935124 SUPPORT Human Clinical

"The most common clinical manifestations of fibromuscular dysplasia (FMD) are hypertension due to renal artery involvement and transient ischemic attack or stroke due to carotid or vertebral artery involvement."

This supports renal fibromuscular dysplasia as a renal artery lesion that causes hypertension.

Inflammatory renal arteriopathy and vasculitis

Arteritis and large-vessel vasculitis, including Takayasu arteritis in pediatric renovascular disease, can inflame and remodel renal arterial walls to produce stenosis and renovascular hypertension.

inflammatory response link ↑ INCREASED blood vessel remodeling link ⚠ ABNORMAL

Downstream

Renal hypoperfusion and RAAS activation Inflammatory renal artery narrowing lowers effective renal arterial inflow.

Show evidence (3 references)

DOI:10.3390/jcm13226778 SUPPORT Human Clinical

"The etiologies of RAS and MAS often involve genetic factors and acquired conditions such as fibromuscular dysplasia and Takayasu arteritis, contributing to their complex clinical presentations."

This identifies Takayasu arteritis as an acquired renovascular stenosis etiology.

PMID:17152333 SUPPORT Human Clinical

"Takayasu arteritis is a chronic vasculitis of unknown origin, affecting mainly the aorta and its main branches. As a result of the inflammation, stenosis, occlusion or dilatation of the involved vessels may occur and cause a wide range of symptoms."

This directly supports inflammation-driven vascular stenosis or occlusion in Takayasu arteritis.

DOI:10.1161/hypertensionaha.121.17004 SUPPORT Human Clinical

"For didactic reasons, we have grouped these different entities into stenotic lesions (neurofibromatosis type 1 and other rare syndromes, dissection, arteritis, and segmental arterial mediolysis) often associated with aortic coarctation and other arterial abnormalities, and nonstenotic lesions,..."

This review includes arteritis among rare stenotic renovascular hypertension mechanisms.

Other rare stenotic and nonstenotic renal artery obstruction

Dissection, segmental arterial mediolysis, aneurysm-related pulsatility, arteriovenous shunting, and extrinsic compression are sparse but recognized rare mechanisms that can impair renal arterial perfusion.

Downstream

Renal hypoperfusion and RAAS activation Rare stenotic or nonstenotic mechanisms can lower effective renal arterial inflow.

Show evidence (1 reference)

DOI:10.1161/hypertensionaha.121.17004 SUPPORT Human Clinical

"For didactic reasons, we have grouped these different entities into stenotic lesions (neurofibromatosis type 1 and other rare syndromes, dissection, arteritis, and segmental arterial mediolysis) often associated with aortic coarctation and other arterial abnormalities, and nonstenotic lesions,..."

This supports rare stenotic and nonstenotic mechanisms that can impair renal perfusion.

Renal hypoperfusion and RAAS activation

Reduced renal arterial inflow lowers perfusion pressure in the affected kidney. The post-stenotic kidney responds through blood-pressure regulatory pathways, including the renin-angiotensin-aldosterone axis, producing renovascular hypertension and contributing to target-organ remodeling.

regulation of blood pressure link ⚠ ABNORMAL response to hypoxia link ↑ INCREASED

Downstream

Ischemic nephropathy and cardiac destabilization Persistent hypoperfusion and hypertension drive kidney dysfunction and cardiopulmonary complications.

Show evidence (1 reference)

PMID:37658875 SUPPORT Human Clinical

"A common cause of RenoVH is renal artery stenosis which acts by reducing blood supply to renal parenchyma and activating the renin-angiotensin-aldosterone axis, often leading to cardiac remodelling."

This directly supports the causal chain from renal artery stenosis to reduced blood supply, RAAS activation, and cardiac remodeling.

Ischemic nephropathy and cardiac destabilization

Chronic renal artery obstruction can progress to ischemic nephropathy, acute kidney injury, and cardiac destabilization syndromes, including recurrent flash pulmonary edema and heart failure admissions.

proximal tubule epithelial cell link

response to hypoxia link ↑ INCREASED

Show evidence (2 references)

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury."

This supports the kidney and cardiopulmonary complications downstream of atherosclerotic renal artery obstruction.

DOI:10.1007/s40620-024-01902-1 SUPPORT Human Clinical

"Atherosclerotic renal artery stenosis may cause hypertension, chronic kidney disease and heart failure, but large randomized control trials to date have shown no major additional benefit of renal revascularization over optimal medical management."

This supports the clinical triad of hypertension, chronic kidney disease, and heart failure associated with atherosclerotic renal artery stenosis.

Thromboembolic renal artery infarction

Thrombus or embolus within the main renal artery or its branches can completely or partially obstruct renal blood supply, producing renal infarction, renal impairment, and, in severe bilateral or allograft cases, kidney replacement therapy requirement.

blood coagulation link ↑ INCREASED

Show evidence (2 references)

DOI:10.4081/aiua.2023.11625 SUPPORT Human Clinical

"Renal artery infarction (RI) is the presence of blood clot in the main renal artery or its branches causing complete or partial obstruction of the blood supply."

This defines acute thrombotic or embolic renal artery obstruction as a renal infarction mechanism.

DOI:10.4081/aiua.2023.11625 SUPPORT Human Clinical

"Its etiology is either related with disorders of the renal vasculature or with cardiovascular diseases."

This supports renal vascular and cardiovascular sources of thromboembolic renal artery infarction.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Cardiovascular 1

Heart failure syndrome Congestive heart failure (HP:0001635)

Show evidence (1 reference)

DOI:10.1007/s40620-024-01902-1 SUPPORT Human Clinical

"Atherosclerotic renal artery stenosis may cause hypertension, chronic kidney disease and heart failure, but large randomized control trials to date have shown no major additional benefit of renal revascularization over optimal medical management."

This supports heart failure as a clinical manifestation associated with atherosclerotic renal artery stenosis.

Genitourinary 4

Chronic kidney disease from ischemic nephropathy Chronic kidney disease (HP:0012622)

Show evidence (2 references)

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury."

This supports progressive chronic kidney disease as a manifestation of atherosclerotic renovascular disease.

DOI:10.1007/s40620-024-01902-1 SUPPORT Human Clinical

"The effect of revascularization was assessed according to the clinical presentation; blood pressure and number of agents in those with renovascular hypertension, delta glomerular filtration rate in those with ischaemic nephropathy and heart failure re-admissions in those with heart failure syndromes."

This clinical cohort assessed ischemic nephropathy as a presentation of atherosclerotic renal artery stenosis.

Acute kidney injury Acute kidney injury (HP:0001919)

Show evidence (1 reference)

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury."

This review explicitly lists acute kidney injury as a manifestation of atherosclerotic renovascular disease.

Renal impairment after infarction Renal insufficiency (HP:0000083)

Show evidence (1 reference)

DOI:10.4081/aiua.2023.11625 SUPPORT Human Clinical

"Kidney replacement therapy was offered to five patients while invasive therapies with thrombus aspiration or catheter directed thrombolysis were performed in two."

This supports severe renal impairment as an outcome of renal artery infarction.

Hematuria in acute renal infarction Hematuria (HP:0000790)

Show evidence (1 reference)

PMID:31624390 SUPPORT Human Clinical

"Hematuria was detected in only 38.5% of the cases on admission."

This cohort supports hematuria as an observed, but not sensitive, renal infarction presentation.

Metabolism 2

Recurrent flash pulmonary edema Pulmonary edema (HP:0100598)

Temporal: RECURRENT

Show evidence (1 reference)

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury."

This supports recurrent flash pulmonary edema as a high-risk presentation.

Fever in acute renal infarction Fever (HP:0001945)

Show evidence (1 reference)

PMID:31624390 SUPPORT Human Clinical

"including abdominal/flank pain (71.2%), nausea (55.8%), lumbar pain (53.9%), vomiting (48.1%), fever (48.1%), and diarrhea (21.2%)."

This acute renal infarction cohort reports fever among common presenting symptoms.

Constitutional 1

Abdominal or flank pain in acute renal infarction Flank pain (HP:0030157)

Show evidence (1 reference)

PMID:31624390 SUPPORT Human Clinical

"including abdominal/flank pain (71.2%), nausea (55.8%), lumbar pain (53.9%), vomiting (48.1%), fever (48.1%), and diarrhea (21.2%)."

This acute renal infarction cohort identifies abdominal or flank pain as the most common presenting symptom.

Other 2

Renal artery stenosis or occlusion Renal artery stenosis (HP:0001920)

Show evidence (2 references)

PMID:19711640 SUPPORT Human Clinical

"The wide range of renal vascular diseases include congenital renal artery and vein variations, aneurysms, arteriovenous malformations (AVMs), renal artery stenosis, renal vein thrombosis, vasculitis, and traumatic injuries, such as dissection and vascular pedicle injury."

This imaging review identifies renal artery stenosis among renal vascular diseases.

DOI:10.3390/jcm13226778 SUPPORT Human Clinical

"RAS is characterized by the narrowing of the renal arteries, while MAS involves the stenosis of the abdominal aorta along with its associated vessels."

This pediatric review defines renal artery stenosis as narrowing of the renal arteries.

Renovascular hypertension Renovascular hypertension (HP:0100817)

Show evidence (2 references)

DOI:10.1161/hypertensionaha.121.17004 SUPPORT Human Clinical

"Renovascular hypertension is one of the most common forms of secondary hypertension."

This supports renovascular hypertension as a central clinical syndrome of renal artery obstruction.

PMID:37658875 SUPPORT Human Clinical

"A common cause of RenoVH is renal artery stenosis which acts by reducing blood supply to renal parenchyma and activating the renin-angiotensin-aldosterone axis, often leading to cardiac remodelling."

This directly links renal artery stenosis to renovascular hypertension physiology.

💊

Treatments

4

Multifactorial medical therapy for atherosclerotic renovascular disease

Action: Pharmacotherapy NCIT:C15986

Most patients with atherosclerotic renal artery stenosis receive intensive medical therapy, including antihypertensive therapy, antiplatelet therapy, lipid-lowering therapy, diabetes optimization when needed, and vascular risk-factor management.

Show evidence (1 reference)

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Atherosclerotic renovascular disease is usually part of a more diffuse atherosclerotic process and requires a combination therapy including antihypertensive, antiplatelet and lipid-lowering agents, as well as optimization of antidiabetic treatment, if needed."

This directly supports multifactorial medical management.

Selected renal artery angioplasty or stenting

Action: angioplasty Ontology label: Angioplasty NCIT:C51999

Revascularization may be considered for carefully selected high-risk patients with clinically important renal artery stenosis, especially severe renovascular hypertension, deteriorating kidney function, heart-failure syndromes, or very severe anatomy after multidisciplinary review. Routine stenting of unselected atherosclerotic disease has limited trial support.

Show evidence (3 references)

DOI:10.1007/s40620-024-01902-1 SUPPORT Human Clinical

"Seventy-nine percent of all revascularized patients had a positive outcome specific to their clinical presentation, with 82% of those with severe hypertension improving blood pressure control, 72% with progressive ischaemic nephropathy having attenuated GFR decline, and no further heart failure..."

This cohort supports selected, phenotype-driven revascularization benefit.

DOI:10.1161/HYPERTENSIONAHA.122.17965 PARTIAL Human Clinical

"However, despite an apparently solid rationale, several randomized clinical trials failed to confirm the favorable effects of percutaneous renal angioplasty on blood pressure control, kidney function, cardiovascular and renal outcomes, previously reported in observational, retrospective and..."

This review limits the treatment claim by summarizing failed randomized trials and explaining why routine angioplasty/stenting enthusiasm declined.

PMID:24245566 PARTIAL Human Clinical

"Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease."

The CORAL randomized trial directly limits routine stenting for unselected atherosclerotic renal artery stenosis.

Balloon angioplasty for renal fibromuscular dysplasia

Action: balloon angioplasty Ontology label: Balloon Angioplasty NCIT:C93007

Primary angioplasty can be used for renal artery fibromuscular dysplasia with hypertension, aiming to improve or cure renovascular hypertension; antihypertensive therapy is used when blood pressure does not normalize.

Show evidence (2 references)

PMID:15935124 SUPPORT Human Clinical

"Patients with renal artery FMD and hypertension should undergo primary angioplasty with the goal of curing the hypertension."

This treatment review supports angioplasty for renal artery FMD-associated hypertension.

PMID:15935124 SUPPORT Human Clinical

"If the blood pressure fails to normalize following angioplasty, the physician should institute antihypertensive medications according to the recommendations of the Joint National Committee on the Prevention, Detection, and Treatment of High Blood Pressure VII."

This supports antihypertensive medication after angioplasty when renovascular hypertension persists.

Anticoagulation and selective thrombolytic treatment for renal infarction

Action: anticoagulation therapy Ontology label: Anticoagulation Therapy NCIT:C63341

Acute renal artery infarction is commonly managed with anticoagulation, and severe cases may require thrombus aspiration or catheter-directed thrombolysis after individualized risk-benefit assessment.

Show evidence (2 references)

DOI:10.4081/aiua.2023.11625 SUPPORT Human Clinical

"Low molecular weight heparins (LMWH) (usually 60-80 mg enoxaparine bid) was the primary treatment, followed by combinations of unfractionated heparin and salicylic acid, apixaban and rivaraxaban, warfarin, acenocoumarol or clopidogrel."

This supports anticoagulation-centered treatment for renal artery infarction case reports.

DOI:10.4081/aiua.2023.11625 PARTIAL Human Clinical

"Interventional treatment could be offered in a minority of more severe cases after carful balancing the risks and benefits."

This supports selective interventional treatment while preserving the authors' caution that it applies to a minority of severe cases.

🌍

Environmental Factors

2

Atherosclerotic cardiovascular risk context

Atherosclerotic renal artery obstruction is enriched with older age and systemic atherosclerotic comorbidity, including end-stage chronic kidney disease, heart failure, coronary artery disease, diabetes, and lipid risk requiring medical risk-factor management.

Show evidence (1 reference)

DOI:10.1161/HYPERTENSIONAHA.122.17965 SUPPORT Human Clinical

"Atherosclerotic renovascular disease is the most frequent cause of renovascular hypertension and its prevalence increases with age and in specific subset of patients, such as those with end-stage chronic kidney disease, heart failure, and coronary artery disease."

This supports older age and systemic vascular disease contexts as risk enrichments for atherosclerotic renovascular disease.

SARS-CoV-2-associated thrombotic state

SARS-CoV-2 infection has been reported as a trigger for renal artery infarction through thromboembolic disease.

Show evidence (1 reference)

DOI:10.4081/aiua.2023.11625 SUPPORT Human Clinical

"Recently, the SARSCoV- 2 virus is an emerging cause of thromboembolic events and the incidence of RI is anticipated to increase after the pandemic."

This systematic review frames SARS-CoV-2-associated thrombosis as a reported renal infarction trigger.

🔬

Biochemical Markers

2

Elevated serum lactate dehydrogenase in acute renal infarction (Elevated)

Context: Acute renal infarction laboratory evaluation

Show evidence (1 reference)

PMID:31624390 SUPPORT Human Clinical

"The levels of serum lactate dehydrogenase, white blood cell count and C-reactive protein were elevated in 86.5%, 67.3%, and 54.5% of cases, respectively."

This cohort supports elevated serum lactate dehydrogenase as a common laboratory clue in acute renal infarction.

Elevated serum D-dimer in acute renal infarction (Elevated)

Context: Acute renal infarction laboratory evaluation

Show evidence (1 reference)

PMID:31624390 SUPPORT Human Clinical

"Elevation of serum D-dimer was only noted in 56.5% of the patients."

This cohort supports D-dimer elevation as an imperfect laboratory clue in acute renal infarction.

🔬

Clinical Trials

1

NCT00081731 PHASE_III COMPLETED

The CORAL trial compared medical therapy plus renal artery stenting with medical therapy alone for hemodynamically significant atherosclerotic renal artery stenosis in patients with systolic hypertension and renal artery stenosis.

Target Phenotypes: Renal artery stenosis ↗ Renovascular hypertension ↗

Show evidence (1 reference)

clinicaltrials:NCT00081731 SUPPORT Human Clinical

"This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis."

The ClinicalTrials.gov summary directly states the trial comparison and target population.

{ }

Source YAML

click to show

name: Renal Artery Obstruction
creation_date: "2026-05-06T18:59:35Z"
updated_date: "2026-05-06T19:49:52Z"
description: >-
  Renal artery obstruction is a renal vascular disorder in which stenosis or
  occlusion of one or both renal arteries reduces renal perfusion. The disorder
  is most often modeled clinically as atherosclerotic renal artery stenosis or
  atherosclerotic renovascular disease, but renal fibromuscular dysplasia,
  pediatric renovascular lesions, thromboembolism, vasculitis, dissection, and
  extrinsic compression can produce the same perfusion-limiting endpoint. Major
  consequences include renovascular hypertension, ischemic nephropathy, acute
  kidney injury, renal infarction, and cardiac destabilization syndromes.
category: Complex
disease_term:
  preferred_term: renal artery obstruction
  term:
    id: MONDO:0006945
    label: renal artery obstruction
parents:
- Vascular disorder
synonyms:
- Renal artery stenosis
- Renal artery occlusion
- Renovascular disease
- Atherosclerotic renovascular disease
- Atherosclerotic renal artery stenosis
- Ischemic nephropathy
pathophysiology:
- name: Atherosclerotic renal artery stenosis
  description: >-
    Atherosclerotic plaque narrows the renal artery lumen, usually as part of a
    diffuse atherosclerotic process. This stenosis reduces downstream renal
    perfusion and is the most common adult mechanism for renovascular
    hypertension and ischemic kidney injury.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: ABNORMAL
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Atherosclerotic renovascular disease is the most frequent cause of renovascular hypertension and its prevalence increases with age and in specific subset of patients, such as those with end-stage chronic kidney disease, heart failure, and coronary artery disease.
    explanation: This review identifies atherosclerotic renovascular disease as the leading adult cause and places it in high-risk vascular comorbidity contexts.
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Atherosclerotic renovascular disease is usually part of a more diffuse atherosclerotic process and requires a combination therapy including antihypertensive, antiplatelet and lipid-lowering agents, as well as optimization of antidiabetic treatment, if needed.
    explanation: This supports systemic atherosclerotic disease and cardiometabolic risk management as central etiologic and treatment context.
  downstream:
  - target: Renal hypoperfusion and RAAS activation
    description: Luminal narrowing lowers perfusion pressure in the post-stenotic kidney.
- name: Renal fibromuscular dysplasia arteriopathy
  description: >-
    Fibromuscular dysplasia is a nonatherosclerotic renal artery arteriopathy
    in which mature vessel-wall remodeling and medial structural disorganization
    narrow renal arterial flow and produce renovascular hypertension.
  cell_types:
  - preferred_term: vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: blood vessel remodeling
    modifier: ABNORMAL
    term:
      id: GO:0001974
      label: blood vessel remodeling
  - preferred_term: collagen fibril organization
    modifier: ABNORMAL
    term:
      id: GO:0030199
      label: collagen fibril organization
  evidence:
  - reference: DOI:10.1161/ATVBAHA.119.313885
    reference_title: "A Novel Recurrent COL5A1 Genetic Variant Is Associated With a Dysplasia-Associated Arterial Disease Exhibiting Dissections and Fibromuscular Dysplasia"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We studied 4 independent probands with the COL5A1 pathogenic variant c.1540G>A, p.(Gly514Ser) who presented with arterial aneurysms, dissections, tortuosity, and mFMD affecting multiple arteries. Arterial medial fibroplasia and smooth muscle cell disorganization were confirmed histologically.
    explanation: This supports an FMD-spectrum structural arteriopathy with mature arterial wall remodeling and smooth muscle disorganization.
  - reference: DOI:10.1161/hypertensionaha.121.17004
    reference_title: "Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Over 95% of cases of renovascular hypertension are due either to atherosclerosis of the main renal artery trunks or to fibromuscular dysplasia.
    explanation: This establishes the two dominant etiologic classes for renovascular renal artery obstruction.
  - reference: PMID:15935124
    reference_title: Fibromuscular Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common clinical manifestations of fibromuscular dysplasia (FMD) are hypertension due to renal artery involvement and transient ischemic attack or stroke due to carotid or vertebral artery involvement.
    explanation: This supports renal fibromuscular dysplasia as a renal artery lesion that causes hypertension.
  downstream:
  - target: Renal hypoperfusion and RAAS activation
    description: Fibromuscular dysplasia narrows renal arterial inflow and lowers downstream perfusion pressure.
- name: Inflammatory renal arteriopathy and vasculitis
  description: >-
    Arteritis and large-vessel vasculitis, including Takayasu arteritis in
    pediatric renovascular disease, can inflame and remodel renal arterial walls
    to produce stenosis and renovascular hypertension.
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: blood vessel remodeling
    modifier: ABNORMAL
    term:
      id: GO:0001974
      label: blood vessel remodeling
  evidence:
  - reference: DOI:10.3390/jcm13226778
    reference_title: Renal Artery Stenosis and Mid-Aortic Syndrome in Children-A Review
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The etiologies of RAS and MAS often involve genetic factors and acquired conditions such as fibromuscular dysplasia and Takayasu arteritis, contributing to their complex clinical presentations.
    explanation: This identifies Takayasu arteritis as an acquired renovascular stenosis etiology.
  - reference: PMID:17152333
    reference_title: "[Takayasu arteritis: a chronic vasculitis that is rare in children]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Takayasu arteritis is a chronic vasculitis of unknown origin, affecting mainly the aorta and its main branches. As a result of the inflammation, stenosis, occlusion or dilatation of the involved vessels may occur and cause a wide range of symptoms.
    explanation: This directly supports inflammation-driven vascular stenosis or occlusion in Takayasu arteritis.
  - reference: DOI:10.1161/hypertensionaha.121.17004
    reference_title: "Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For didactic reasons, we have grouped these different entities into stenotic lesions (neurofibromatosis type 1 and other rare syndromes, dissection, arteritis, and segmental arterial mediolysis) often associated with aortic coarctation and other arterial abnormalities, and nonstenotic lesions, where hypertension is secondary to compression of adjacent arteries and changes in arterial pulsatility (aneurysm) or to the formation of a shunt, leading to kidney ischemia (arteriovenous fistula).
    explanation: This review includes arteritis among rare stenotic renovascular hypertension mechanisms.
  downstream:
  - target: Renal hypoperfusion and RAAS activation
    description: Inflammatory renal artery narrowing lowers effective renal arterial inflow.
- name: Other rare stenotic and nonstenotic renal artery obstruction
  description: >-
    Dissection, segmental arterial mediolysis, aneurysm-related pulsatility,
    arteriovenous shunting, and extrinsic compression are sparse but recognized
    rare mechanisms that can impair renal arterial perfusion.
  evidence:
  - reference: DOI:10.1161/hypertensionaha.121.17004
    reference_title: "Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For didactic reasons, we have grouped these different entities into stenotic lesions (neurofibromatosis type 1 and other rare syndromes, dissection, arteritis, and segmental arterial mediolysis) often associated with aortic coarctation and other arterial abnormalities, and nonstenotic lesions, where hypertension is secondary to compression of adjacent arteries and changes in arterial pulsatility (aneurysm) or to the formation of a shunt, leading to kidney ischemia (arteriovenous fistula).
    explanation: This supports rare stenotic and nonstenotic mechanisms that can impair renal perfusion.
  downstream:
  - target: Renal hypoperfusion and RAAS activation
    description: Rare stenotic or nonstenotic mechanisms can lower effective renal arterial inflow.
- name: Renal hypoperfusion and RAAS activation
  description: >-
    Reduced renal arterial inflow lowers perfusion pressure in the affected
    kidney. The post-stenotic kidney responds through blood-pressure regulatory
    pathways, including the renin-angiotensin-aldosterone axis, producing
    renovascular hypertension and contributing to target-organ remodeling.
  biological_processes:
  - preferred_term: regulation of blood pressure
    modifier: ABNORMAL
    term:
      id: GO:0008217
      label: regulation of blood pressure
  - preferred_term: response to hypoxia
    modifier: INCREASED
    term:
      id: GO:0001666
      label: response to hypoxia
  evidence:
  - reference: PMID:37658875
    reference_title: Cardiovascular outcomes improve in children with renovascular hypertension following endovascular and surgical interventions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A common cause of RenoVH is renal artery stenosis which acts by reducing blood supply to renal parenchyma and activating the renin-angiotensin-aldosterone axis, often leading to cardiac remodelling.
    explanation: This directly supports the causal chain from renal artery stenosis to reduced blood supply, RAAS activation, and cardiac remodeling.
  downstream:
  - target: Ischemic nephropathy and cardiac destabilization
    description: Persistent hypoperfusion and hypertension drive kidney dysfunction and cardiopulmonary complications.
- name: Ischemic nephropathy and cardiac destabilization
  description: >-
    Chronic renal artery obstruction can progress to ischemic nephropathy,
    acute kidney injury, and cardiac destabilization syndromes, including
    recurrent flash pulmonary edema and heart failure admissions.
  cell_types:
  - preferred_term: proximal tubule epithelial cell
    term:
      id: CL:0002306
      label: epithelial cell of proximal tubule
  biological_processes:
  - preferred_term: response to hypoxia
    modifier: INCREASED
    term:
      id: GO:0001666
      label: response to hypoxia
  evidence:
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury.
    explanation: This supports the kidney and cardiopulmonary complications downstream of atherosclerotic renal artery obstruction.
  - reference: DOI:10.1007/s40620-024-01902-1
    reference_title: "Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Atherosclerotic renal artery stenosis may cause hypertension, chronic kidney disease and heart failure, but large randomized control trials to date have shown no major additional benefit of renal revascularization over optimal medical management.
    explanation: This supports the clinical triad of hypertension, chronic kidney disease, and heart failure associated with atherosclerotic renal artery stenosis.
- name: Thromboembolic renal artery infarction
  description: >-
    Thrombus or embolus within the main renal artery or its branches can
    completely or partially obstruct renal blood supply, producing renal
    infarction, renal impairment, and, in severe bilateral or allograft cases,
    kidney replacement therapy requirement.
  biological_processes:
  - preferred_term: blood coagulation
    modifier: INCREASED
    term:
      id: GO:0007596
      label: blood coagulation
  evidence:
  - reference: DOI:10.4081/aiua.2023.11625
    reference_title: "Renal artery infarction in the SARS-Cov-2 era: A systematic review of case reports"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal artery infarction (RI) is the presence of blood clot in the main renal artery or its branches causing complete or partial obstruction of the blood supply.
    explanation: This defines acute thrombotic or embolic renal artery obstruction as a renal infarction mechanism.
  - reference: DOI:10.4081/aiua.2023.11625
    reference_title: "Renal artery infarction in the SARS-Cov-2 era: A systematic review of case reports"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its etiology is either related with disorders of the renal vasculature or with cardiovascular diseases.
    explanation: This supports renal vascular and cardiovascular sources of thromboembolic renal artery infarction.
phenotypes:
- category: Cardiovascular
  name: Renal artery stenosis or occlusion
  diagnostic: true
  description: Stenosis or occlusion of the renal artery is the defining vascular lesion.
  phenotype_term:
    preferred_term: Renal artery stenosis
    term:
      id: HP:0001920
      label: Renal artery stenosis
  evidence:
  - reference: PMID:19711640
    reference_title: Imaging of renovascular disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The wide range of renal vascular diseases include congenital renal artery and vein variations, aneurysms, arteriovenous malformations (AVMs), renal artery stenosis, renal vein thrombosis, vasculitis, and traumatic injuries, such as dissection and vascular pedicle injury.
    explanation: This imaging review identifies renal artery stenosis among renal vascular diseases.
  - reference: DOI:10.3390/jcm13226778
    reference_title: Renal Artery Stenosis and Mid-Aortic Syndrome in Children-A Review
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      RAS is characterized by the narrowing of the renal arteries, while MAS involves the stenosis of the abdominal aorta along with its associated vessels.
    explanation: This pediatric review defines renal artery stenosis as narrowing of the renal arteries.
- category: Cardiovascular
  name: Renovascular hypertension
  description: Hypertension arises when renal artery obstruction reduces renal perfusion and activates blood-pressure regulatory pathways.
  phenotype_term:
    preferred_term: Renovascular hypertension
    term:
      id: HP:0100817
      label: Renovascular hypertension
  evidence:
  - reference: DOI:10.1161/hypertensionaha.121.17004
    reference_title: "Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renovascular hypertension is one of the most common forms of secondary hypertension.
    explanation: This supports renovascular hypertension as a central clinical syndrome of renal artery obstruction.
  - reference: PMID:37658875
    reference_title: Cardiovascular outcomes improve in children with renovascular hypertension following endovascular and surgical interventions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A common cause of RenoVH is renal artery stenosis which acts by reducing blood supply to renal parenchyma and activating the renin-angiotensin-aldosterone axis, often leading to cardiac remodelling.
    explanation: This directly links renal artery stenosis to renovascular hypertension physiology.
- category: Renal
  name: Chronic kidney disease from ischemic nephropathy
  description: Chronic renal hypoperfusion can produce progressive ischemic nephropathy and chronic kidney disease.
  phenotype_term:
    preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease
  evidence:
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury.
    explanation: This supports progressive chronic kidney disease as a manifestation of atherosclerotic renovascular disease.
  - reference: DOI:10.1007/s40620-024-01902-1
    reference_title: "Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The effect of revascularization was assessed according to the clinical presentation; blood pressure and number of agents in those with renovascular hypertension, delta glomerular filtration rate in those with ischaemic nephropathy and heart failure re-admissions in those with heart failure syndromes.
    explanation: This clinical cohort assessed ischemic nephropathy as a presentation of atherosclerotic renal artery stenosis.
- category: Renal
  name: Acute kidney injury
  description: Acute or rapidly worsening renal hypoperfusion can cause acute kidney injury.
  phenotype_term:
    preferred_term: Acute kidney injury
    term:
      id: HP:0001919
      label: Acute kidney injury
  evidence:
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury.
    explanation: This review explicitly lists acute kidney injury as a manifestation of atherosclerotic renovascular disease.
- category: Respiratory
  name: Recurrent flash pulmonary edema
  description: High-risk atherosclerotic renal artery obstruction can present with recurrent flash pulmonary edema or heart-failure destabilization.
  phenotype_term:
    preferred_term: Flash pulmonary edema
    term:
      id: HP:0100598
      label: Pulmonary edema
    temporality: RECURRENT
  evidence:
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Besides hypertension, atherosclerotic renovascular disease is responsible for several clinical manifestations, including life-threatening conditions, such as recurrent flash pulmonary edema, rapidly progressive chronic kidney disease, or acute kidney injury.
    explanation: This supports recurrent flash pulmonary edema as a high-risk presentation.
- category: Cardiovascular
  name: Heart failure syndrome
  description: Renovascular disease can destabilize heart failure and lead to recurrent admissions in selected high-risk patients.
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: DOI:10.1007/s40620-024-01902-1
    reference_title: "Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Atherosclerotic renal artery stenosis may cause hypertension, chronic kidney disease and heart failure, but large randomized control trials to date have shown no major additional benefit of renal revascularization over optimal medical management.
    explanation: This supports heart failure as a clinical manifestation associated with atherosclerotic renal artery stenosis.
- category: Renal
  name: Renal impairment after infarction
  description: Acute renal artery infarction can leave impaired kidney function or require kidney replacement therapy in severe cases.
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
  evidence:
  - reference: DOI:10.4081/aiua.2023.11625
    reference_title: "Renal artery infarction in the SARS-Cov-2 era: A systematic review of case reports"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Kidney replacement therapy was offered to five patients while invasive therapies with thrombus aspiration or catheter directed thrombolysis were performed in two.
    explanation: This supports severe renal impairment as an outcome of renal artery infarction.
- category: Renal
  name: Abdominal or flank pain in acute renal infarction
  description: Acute renal artery infarction commonly presents with abdominal or flank pain.
  phenotype_term:
    preferred_term: Flank pain
    term:
      id: HP:0030157
      label: Flank pain
  evidence:
  - reference: PMID:31624390
    reference_title: "[Clinical characteristics of patients with acute renal infarction: an analysis of 52 patients in a single center]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including abdominal/flank pain (71.2%), nausea (55.8%), lumbar pain (53.9%), vomiting (48.1%), fever (48.1%), and diarrhea (21.2%).
    explanation: This acute renal infarction cohort identifies abdominal or flank pain as the most common presenting symptom.
- category: Renal
  name: Hematuria in acute renal infarction
  description: Hematuria can occur at presentation in acute renal artery infarction.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
  evidence:
  - reference: PMID:31624390
    reference_title: "[Clinical characteristics of patients with acute renal infarction: an analysis of 52 patients in a single center]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hematuria was detected in only 38.5% of the cases on admission.
    explanation: This cohort supports hematuria as an observed, but not sensitive, renal infarction presentation.
- category: Constitutional
  name: Fever in acute renal infarction
  description: Fever is a systemic presenting symptom reported in acute renal artery infarction.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:31624390
    reference_title: "[Clinical characteristics of patients with acute renal infarction: an analysis of 52 patients in a single center]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including abdominal/flank pain (71.2%), nausea (55.8%), lumbar pain (53.9%), vomiting (48.1%), fever (48.1%), and diarrhea (21.2%).
    explanation: This acute renal infarction cohort reports fever among common presenting symptoms.
environmental:
- name: Atherosclerotic cardiovascular risk context
  description: >-
    Atherosclerotic renal artery obstruction is enriched with older age and
    systemic atherosclerotic comorbidity, including end-stage chronic kidney
    disease, heart failure, coronary artery disease, diabetes, and lipid risk
    requiring medical risk-factor management.
  evidence:
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Atherosclerotic renovascular disease is the most frequent cause of renovascular hypertension and its prevalence increases with age and in specific subset of patients, such as those with end-stage chronic kidney disease, heart failure, and coronary artery disease.
    explanation: This supports older age and systemic vascular disease contexts as risk enrichments for atherosclerotic renovascular disease.
- name: SARS-CoV-2-associated thrombotic state
  description: SARS-CoV-2 infection has been reported as a trigger for renal artery infarction through thromboembolic disease.
  evidence:
  - reference: DOI:10.4081/aiua.2023.11625
    reference_title: "Renal artery infarction in the SARS-Cov-2 era: A systematic review of case reports"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recently, the SARSCoV- 2 virus is an emerging cause of thromboembolic events and the incidence of RI is anticipated to increase after the pandemic.
    explanation: This systematic review frames SARS-CoV-2-associated thrombosis as a reported renal infarction trigger.
diagnosis:
- name: Renal vascular imaging
  description: >-
    Doppler ultrasound, CT angiography, MR angiography, catheter angiography,
    and functional assessment are used to detect renal artery stenosis or
    occlusion, define lesion severity, evaluate downstream kidney viability,
    and select patients for medical therapy or revascularization.
  diagnosis_term:
    preferred_term: angiography
    term:
      id: MAXO:0001259
      label: angiography
  results: Imaging demonstrates renal artery stenosis, complete occlusion, thrombus, infarction, or downstream renal perfusion impairment.
  evidence:
  - reference: PMID:19711640
    reference_title: Imaging of renovascular disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A variety of different imaging techniques have been used for the diagnosis of renal vascular diseases.
    explanation: This supports renal vascular imaging as the core diagnostic modality.
  - reference: PMID:19711640
    reference_title: Imaging of renovascular disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this article, we discuss the role of invasive and noninvasive imaging in each of these abnormalities and their typical features.
    explanation: This supports both invasive and noninvasive imaging in renal vascular disease assessment.
biochemical:
- name: Elevated serum lactate dehydrogenase in acute renal infarction
  presence: Elevated
  context: Acute renal infarction laboratory evaluation
  evidence:
  - reference: PMID:31624390
    reference_title: "[Clinical characteristics of patients with acute renal infarction: an analysis of 52 patients in a single center]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The levels of serum lactate dehydrogenase, white blood cell count and C-reactive protein were elevated in 86.5%, 67.3%, and 54.5% of cases, respectively.
    explanation: This cohort supports elevated serum lactate dehydrogenase as a common laboratory clue in acute renal infarction.
- name: Elevated serum D-dimer in acute renal infarction
  presence: Elevated
  context: Acute renal infarction laboratory evaluation
  evidence:
  - reference: PMID:31624390
    reference_title: "[Clinical characteristics of patients with acute renal infarction: an analysis of 52 patients in a single center]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Elevation of serum D-dimer was only noted in 56.5% of the patients.
    explanation: This cohort supports D-dimer elevation as an imperfect laboratory clue in acute renal infarction.
treatments:
- name: Multifactorial medical therapy for atherosclerotic renovascular disease
  description: >-
    Most patients with atherosclerotic renal artery stenosis receive intensive
    medical therapy, including antihypertensive therapy, antiplatelet therapy,
    lipid-lowering therapy, diabetes optimization when needed, and vascular
    risk-factor management.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Atherosclerotic renovascular disease is usually part of a more diffuse atherosclerotic process and requires a combination therapy including antihypertensive, antiplatelet and lipid-lowering agents, as well as optimization of antidiabetic treatment, if needed.
    explanation: This directly supports multifactorial medical management.
- name: Selected renal artery angioplasty or stenting
  description: >-
    Revascularization may be considered for carefully selected high-risk
    patients with clinically important renal artery stenosis, especially severe
    renovascular hypertension, deteriorating kidney function, heart-failure
    syndromes, or very severe anatomy after multidisciplinary review. Routine
    stenting of unselected atherosclerotic disease has limited trial support.
  treatment_term:
    preferred_term: angioplasty
    term:
      id: NCIT:C51999
      label: Angioplasty
  evidence:
  - reference: DOI:10.1007/s40620-024-01902-1
    reference_title: "Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seventy-nine percent of all revascularized patients had a positive outcome specific to their clinical presentation, with 82% of those with severe hypertension improving blood pressure control, 72% with progressive ischaemic nephropathy having attenuated GFR decline, and no further heart failure admissions in those with heart failure.
    explanation: This cohort supports selected, phenotype-driven revascularization benefit.
  - reference: DOI:10.1161/HYPERTENSIONAHA.122.17965
    reference_title: "Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, despite an apparently solid rationale, several randomized clinical trials failed to confirm the favorable effects of percutaneous renal angioplasty on blood pressure control, kidney function, cardiovascular and renal outcomes, previously reported in observational, retrospective and single-center cohorts, switching off the enthusiasm for this procedure.
    explanation: This review limits the treatment claim by summarizing failed randomized trials and explaining why routine angioplasty/stenting enthusiasm declined.
  - reference: PMID:24245566
    reference_title: Stenting and medical therapy for atherosclerotic renal-artery stenosis.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease.
    explanation: The CORAL randomized trial directly limits routine stenting for unselected atherosclerotic renal artery stenosis.
- name: Balloon angioplasty for renal fibromuscular dysplasia
  description: >-
    Primary angioplasty can be used for renal artery fibromuscular dysplasia
    with hypertension, aiming to improve or cure renovascular hypertension;
    antihypertensive therapy is used when blood pressure does not normalize.
  treatment_term:
    preferred_term: balloon angioplasty
    term:
      id: NCIT:C93007
      label: Balloon Angioplasty
  evidence:
  - reference: PMID:15935124
    reference_title: Fibromuscular Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with renal artery FMD and hypertension should undergo primary angioplasty with the goal of curing the hypertension.
    explanation: This treatment review supports angioplasty for renal artery FMD-associated hypertension.
  - reference: PMID:15935124
    reference_title: Fibromuscular Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If the blood pressure fails to normalize following angioplasty, the physician should institute antihypertensive medications according to the recommendations of the Joint National Committee on the Prevention, Detection, and Treatment of High Blood Pressure VII.
    explanation: This supports antihypertensive medication after angioplasty when renovascular hypertension persists.
- name: Anticoagulation and selective thrombolytic treatment for renal infarction
  description: >-
    Acute renal artery infarction is commonly managed with anticoagulation, and
    severe cases may require thrombus aspiration or catheter-directed
    thrombolysis after individualized risk-benefit assessment.
  treatment_term:
    preferred_term: anticoagulation therapy
    term:
      id: NCIT:C63341
      label: Anticoagulation Therapy
  evidence:
  - reference: DOI:10.4081/aiua.2023.11625
    reference_title: "Renal artery infarction in the SARS-Cov-2 era: A systematic review of case reports"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Low molecular weight heparins (LMWH) (usually 60-80 mg enoxaparine bid) was the primary treatment, followed by combinations of unfractionated heparin and salicylic acid, apixaban and rivaraxaban, warfarin, acenocoumarol or clopidogrel.
    explanation: This supports anticoagulation-centered treatment for renal artery infarction case reports.
  - reference: DOI:10.4081/aiua.2023.11625
    reference_title: "Renal artery infarction in the SARS-Cov-2 era: A systematic review of case reports"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Interventional treatment could be offered in a minority of more severe cases after carful balancing the risks and benefits.
    explanation: This supports selective interventional treatment while preserving the authors' caution that it applies to a minority of severe cases.
clinical_trials:
- name: NCT00081731
  phase: PHASE_III
  status: COMPLETED
  description: >-
    The CORAL trial compared medical therapy plus renal artery stenting with
    medical therapy alone for hemodynamically significant atherosclerotic renal
    artery stenosis in patients with systolic hypertension and renal artery
    stenosis.
  target_phenotypes:
  - preferred_term: Renal artery stenosis
    term:
      id: HP:0001920
      label: Renal artery stenosis
  - preferred_term: Renovascular hypertension
    term:
      id: HP:0100817
      label: Renovascular hypertension
  evidence:
  - reference: clinicaltrials:NCT00081731
    reference_title: Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
    explanation: The ClinicalTrials.gov summary directly states the trial comparison and target population.
review_notes: >-
  Falcon deep research highlighted acute renal infarction, FMD-related renal
  artery stenosis, high-risk atherosclerotic renovascular disease, and pediatric
  renovascular disease. One Falcon citation mapping attached renal-infarction
  content to a COL5A1/FMD paper, so renal-infarction claims here use fetched
  renal-infarction abstracts instead. No genetic section was added because renal
  artery obstruction is a broad vascular endpoint rather than a discrete
  Mendelian disorder; FMD-specific genetic susceptibility belongs primarily on
  the Fibromuscular Dysplasia page.
datasets:

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 37 citations 2026-05-06T15:24:15.070511

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Renal Artery Obstruction
MONDO ID: (if available)
Category: Complex

Research Objectives

Please provide a comprehensive research report on Renal Artery Obstruction covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Renal Artery Obstruction (Renal Artery Obstruction / Renal Artery Stenosis / Renal Artery Occlusion)

Executive summary (current understanding)

Renal artery obstruction (RAO) is a vascular condition in which blood flow to the kidney is limited by stenosis or occlusion of the main renal artery or major branches. In practice, RAO is an umbrella term encompassing (i) chronic, usually atherosclerotic renal artery stenosis (often discussed as atherosclerotic renovascular disease, ARVD), (ii) non-atherosclerotic stenosis such as renal-artery fibromuscular dysplasia (FMD), and (iii) acute occlusion from thromboembolism/thrombosis causing renal infarction. The clinical syndromes range from asymptomatic disease to renovascular hypertension, progressive chronic kidney disease (ischaemic nephropathy), acute kidney injury, and cardiac destabilisation syndromes including recurrent “flash” pulmonary oedema (Pickering syndrome). Evidence from large randomized trials shows that routine renal-artery stenting in unselected ARVD does not reduce major renal/cardiovascular events compared with optimized medical therapy, but contemporary guidelines and recent cohort data support revascularization for carefully selected high-risk presentations (e.g., flash pulmonary oedema, refractory hypertension, rapid loss of kidney function). (cooper2014stentingandmedical pages 1-2, theodorakopoulou2024guidelinesforthe pages 10-11, bhailis2024improvingoutcomesin pages 10-11)

1. Disease information

1.1 Definition and scope

Renal Artery Obstruction (RAO) refers to partial or complete obstruction of renal arterial blood flow. In clinical literature this is often operationalized as renal artery stenosis (RAS) (luminal narrowing) or renal artery occlusion (complete obstruction), and frequently discussed under the syndromic term atherosclerotic renovascular disease (ARVD) when atherosclerosis is the underlying cause. (pappaccogli2023endovascularversusmedical pages 1-5, kumar2010naturalhistoryand pages 2-2)

1.2 Key identifiers and ontology mappings

MeSH (Medical Subject Headings): Renal Artery Obstruction D012078 (explicitly listed in multiple ClinicalTrials.gov records). (NCT00885768 chunk 1, NCT01208714 chunk 3)
MONDO: In OpenTargets, “renal artery obstruction” appears as an EFO disease concept, but no MONDO identifier for renal artery obstruction was retrieved in the available evidence. (NCT00885768 chunk 1)
ICD-10/ICD-11, OMIM, Orphanet: Not retrieved in the available full-text evidence in this run; these identifiers should be populated from dedicated ontology resources (ICD/Orphanet/OMIM) in a separate lookup step.

1.3 Synonyms and alternative names (as used in evidence)

Controlled vocabulary and common terms used to describe the entity include: - “renal artery obstruction” (MeSH term) - “renal artery stenosis” / “renal-artery stenosis” (often abbreviated RAS) - “renovascular disease” - “renal artery occlusion” - “atherosclerotic renovascular disease” / “atherosclerotic renal artery stenosis” (ARVD/ARAS) These terms were explicitly used as MeSH/text-word definitions for ARVD in the natural-history review and in clinical trial registries. (kumar2010naturalhistoryand pages 2-2, NCT01208714 chunk 3)

1.4 Evidence source types

The information summarized here is derived from: - Aggregated disease-level evidence: reviews and guidelines (2023–2024 prioritized), systematic reviews, and randomized trial reports. (pappaccogli2023endovascularversusmedical pages 1-5, theodorakopoulou2024guidelinesforthe pages 10-11, cooper2014stentingandmedical pages 1-2) - Clinical trial registries (ClinicalTrials.gov) with MeSH ontology tagging and eligibility thresholds. (NCT01208714 chunk 3) - Cohort/real-world observational evidence including multidisciplinary-team (MDT) selection for revascularization. (bhailis2024improvingoutcomesin pages 10-11)

2. Etiology

2.1 Disease causal factors (primary causes)

1) Atherosclerotic renal artery stenosis / ARVD - ARVD is described as the most frequent cause of renovascular hypertension and is typically part of systemic atherosclerosis. (pappaccogli2023endovascularversusmedical pages 1-5)

2) Fibromuscular dysplasia (FMD)-related renal artery stenosis - FMD is a non-atherosclerotic arteriopathy commonly affecting renal arteries (and carotid arteries), typically diagnosed by angiographic features such as a “string-of-beads” appearance in adults. (theodorakopoulou2024guidelinesforthe pages 10-11, pytlos2024renalarterystenosis pages 1-2)

3) Acute thrombotic/embolic obstruction → renal infarction - Renal infarction is defined as a blood clot in the main renal artery or branches causing partial/complete obstruction of blood supply, often due to cardiovascular disease or renal vascular disorders, and described as increasingly recognized in the SARS-CoV-2 era. (richer2020anovelrecurrent pages 8-9)

2.2 Risk factors

For ARVD (atherosclerotic RAO) - Age: prevalence increases with age. (pappaccogli2023endovascularversusmedical pages 1-5) - Systemic atherosclerotic disease: enriched in patients with coronary artery disease and heart failure. (pappaccogli2023endovascularversusmedical pages 1-5) - Diabetes and baseline renal dysfunction are associated with worse progression/outcomes in natural-history data. (kumar2010naturalhistoryand pages 4-5)

For renal infarction (acute occlusion) - In the COVID-era systematic review, renal infarction was framed as thrombotic disease, often occurring despite thromboprophylaxis and sometimes with extrarenal thromboembolism. (richer2020anovelrecurrent pages 8-9)

Pediatric renovascular disease - Etiologies in children include FMD, mid-aortic syndrome (MAS), Takayasu arteritis, Kawasaki disease, syndromic causes (e.g., NF1), trauma, radiation, and extraluminal tumor compression. (pytlos2024renalarterystenosis pages 1-2)

2.3 Protective factors

No explicit genetic or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No explicit gene–environment interaction evidence was identified in the retrieved sources.

3. Phenotypes (clinical presentation)

3.1 Core phenotypes for ARVD / chronic RAO

Clinical manifestations span: - Renovascular hypertension, including resistant/uncontrolled hypertension. (bhailis2024improvingoutcomesin pages 2-3) - Ischaemic nephropathy (progressive kidney dysfunction downstream of stenosis). (bhailis2024improvingoutcomesin pages 1-2) - Cardiac destabilisation syndromes including sudden pulmonary oedema and recurrent heart-failure admissions. (bhailis2024improvingoutcomesin pages 2-3) - Severe presentations noted in reviews include “recurrent flash pulmonary oedema, rapidly progressive chronic kidney disease or acute kidney injury.” (direct quote from abstract-level content summarized in the ARVD review) (pappaccogli2023endovascularversusmedical pages 1-5)

HPO term suggestions (non-exhaustive) - Hypertension (HP:0000822) - Resistant hypertension (not a canonical single HPO term; map to HP:0000822 plus clinical modifier) - Pulmonary edema (HP:0002204) - Congestive heart failure (HP:0001635) - Chronic kidney disease (HP:0012622) - Acute kidney injury (HP:0001919)

3.2 Phenotypes for acute renal artery occlusion / renal infarction

In the COVID-era systematic review and case literature, renal infarction is commonly symptomatic and often presents with nonspecific symptoms. - The 2023 case report review noted renal infarction is “extremely rare,” and that “more than 95% of cases are symptomatic” (quote from abstract). (richer2020anovelrecurrent pages 8-9)

HPO term suggestions - Flank pain (HP:0030834) - Abdominal pain (HP:0002027) - Hematuria (HP:0000790) - Fever (HP:0001945) - Elevated lactate dehydrogenase (LDH) (map to laboratory phenotype; HPO has HP:0031950 “Elevated circulating lactate dehydrogenase level”) - Acute kidney injury (HP:0001919) - Anuria (HP:0003779) (for bilateral occlusion presentations)

3.3 Pediatric renovascular disease phenotypes

RAS and MAS are described as “significant yet under-recognized causes of pediatric hypertension.” (pytlos2024renalarterystenosis pages 1-2)

HPO term suggestions - Pediatric hypertension (map to HP:0000822 with age-of-onset annotation)

4. Genetic / molecular information

4.1 Causal genes

Renal artery obstruction as a broad category is not primarily a Mendelian disease. However, FMD-spectrum arteriopathy may include monogenic contributors/modifiers.

COL5A1 (collagen type V alpha 1 chain) - Richer et al. reported recurrent COL5A1 c.1540G>A, p.(Gly514Ser) associated with a dysplasia-associated arterial disease with multifocal FMD and dissections. (richer2020anovelrecurrent pages 1-2)

4.2 Pathogenic variants and variant details (FMD-spectrum)

Variant: COL5A1 c.1540G>A, p.(Gly514Ser) (also referred to as G514S). (richer2020anovelrecurrent pages 1-2)
In an mFMD exome cohort (n=264), deleterious COL5A1 variants were identified in ≈2.7% of cases and were associated with arterial dissections (P=0.005). (richer2020anovelrecurrent pages 1-2)
The paper notes the recurring variant is absent from gnomAD and lies on a shared haplotype consistent with a founder effect. (richer2020anovelrecurrent pages 1-2)

Mechanistic inference (protein-level) reported - Structural modeling suggested Gly→Ser substitution “create[s] an externalized residue” in the collagenous region, plausibly affecting collagen fibrillogenesis and vascular integrity. (richer2020anovelrecurrent pages 5-7)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

No additional modifiers, epigenetic changes, or chromosomal abnormalities were found in the retrieved evidence.

5. Environmental information

ARVD is strongly linked to systemic atherosclerosis; however, explicit environmental exposures (toxins/pollution) were not discussed in the retrieved evidence. Acute renal infarction can occur in systemic prothrombotic states and was described in association with SARS-CoV-2 infection. (richer2020anovelrecurrent pages 8-9)

6. Mechanism / pathophysiology

6.1 ARVD causal chain (hemodynamic ischemia → kidney dysfunction and systemic effects)

Trigger: atherosclerotic narrowing of renal artery reduces perfusion.
Intermediate processes: kidney ischemia/hypoxia and progressive parenchymal and microvascular damage (ischaemic nephropathy).
Downstream clinical syndromes: resistant hypertension, progressive CKD, AKI, and cardiac destabilisation syndromes (flash pulmonary oedema/heart failure). (bhailis2024improvingoutcomesin pages 2-3, pappaccogli2023endovascularversusmedical pages 15-20)

A key emerging concept is the renal “penumbra”—a post-stenotic kidney that is hypoxic yet potentially salvageable. Pappaccogli et al. summarize functional imaging proposals, including BOLD-MRI to: - “Assess kidney’s renal oxygenation” and - “Differentiate hypoxic but still functionable and salvable poststenotic kidney from hypoxic and functionally dead and unsalvable poststenotic kidney.” (direct quotes) (pappaccogli2023endovascularversusmedical pages 32-35)

RAAS involvement - RAAS involvement is referenced in the ARVD decisional framework and broader hypertension/CKD context; detailed RAAS molecular cascade was not explicitly delineated in retrieved full text. (pappaccogli2023endovascularversusmedical pages 32-35)

6.2 FMD-spectrum vascular wall pathology

Richer et al. report histology consistent with medial fibroplasia and vascular wall structural abnormalities in COL5A1 variant carriers, including increased medial collagen, smooth muscle cell disorganization, and elastin fragmentation. (richer2020anovelrecurrent pages 7-8)

6.3 GO / CL term suggestions (mechanism-linked)

GO Biological Process (suggested) - Response to hypoxia (GO:0001666) - Renin–angiotensin system regulation of blood pressure (GO mapping not provided in evidence; suggested) - Extracellular matrix organization (GO:0030198) - Collagen fibril organization (GO:0030199)

Cell types (CL; suggested) - Vascular smooth muscle cell (CL:0000192) - Endothelial cell (CL:0000115) - Renal tubular epithelial cell (broad; e.g., proximal tubule epithelial cell CL:0002308)

7. Anatomical structures affected

Primary - Renal artery (main renal artery and branches) and downstream kidney parenchyma. (richer2020anovelrecurrent pages 8-9)

Secondary - Cardiovascular system: heart failure/pulmonary oedema syndromes in ARVD. (bhailis2024improvingoutcomesin pages 2-3)

UBERON suggestions - Kidney (UBERON:0002113) - Renal artery (UBERON term; exact ID not retrieved in evidence) - Renal cortex (UBERON:0001225)

8. Temporal development

ARVD - Often chronic and progressive; natural history includes progression of stenosis and possible total occlusion over years. (kumar2010naturalhistoryand pages 2-2)

Renal infarction - Often acute/subacute onset; COVID-era cases were commonly diagnosed within a month of infection. (richer2020anovelrecurrent pages 8-9)

9. Inheritance and population

9.1 Epidemiology (selected quantitative data)

ARVD prevalence estimates (adult) - In the 2023 Hypertension review, ARVD is estimated to account for ~1–2% of hypertension overall, and ~7% of adults >65 years have RAS >60%. Higher prevalence is reported in specific populations: 10–12% in end-stage renal disease, 15–30% with coronary artery disease, and up to 50% in heart failure. (pappaccogli2023endovascularversusmedical pages 1-5)

Pediatric - Pediatric arterial hypertension prevalence is ~4%; renovascular disease accounts for 5–10% of secondary hypertension in children; MAS is 0.5–2% of aortic stenosis; 20–48% of children with renovascular hypertension may have combined renal-artery and mid-aortic narrowing. (pytlos2024renalarterystenosis pages 1-2)

9.2 Natural history/progression (ARVD)

In one cohort summarized in the natural history review: progression occurred in 44% over mean 52 months, with 16% progressing to total occlusion; progression to complete occlusion was 39% in the 75–99% stenosis group vs 5% in the <50% group. (kumar2010naturalhistoryand pages 2-2)

9.3 Genetic etiology population notes

COL5A1 c.1540G>A p.(Gly514Ser) is described as recurring on a shared haplotype consistent with a founder effect; deleterious COL5A1 variants appear in ≈2.7% of an mFMD cohort. (richer2020anovelrecurrent pages 1-2)

10. Diagnostics

10.1 Clinical tests and biomarkers

ARVD/stenosis - The diagnostic approach emphasizes imaging confirmation and evaluation of kidney viability. - Proteinuria/albuminuria is used as a marker of established parenchymal damage in ischemic nephropathy phenotyping (ACR >30 mg/mmol or PCR >50 mg/mol). (bhailis2024improvingoutcomesin pages 2-3)

Renal infarction - The COVID-era review notes serum LDH and D-dimers are frequently elevated; contrast-enhanced CT is a key diagnostic modality. (richer2020anovelrecurrent pages 8-9)

10.2 Imaging

Angiography is described as the gold standard in registry documentation. (NCT00885768 chunk 1)
CTA and contrast-enhanced MRA are preferred imaging modalities in the 2024 MDT cohort. (bhailis2024improvingoutcomesin pages 2-3)
Non-contrast MRA is used for advanced CKD (GFR <30) in that cohort. (bhailis2024improvingoutcomesin pages 2-3)
Duplex ultrasound parameters noted in a 2024 review excerpt include renal–aortic ratio (RAR) ≥3.5 and flow velocities, and caution that CTA/MRA may overestimate stenosis. (piechocki2024…peripheral pages 13-15)

10.3 Functional/advanced diagnostics (emerging)

Functional imaging proposals include BOLD-MRI for renal oxygenation/penumbra detection and physiologic assessment via translesional pressure gradients, plus biomarkers such as NGAL and FGF-23. (pappaccogli2023endovascularversusmedical pages 32-35)

10.4 Diagnostic thresholds used in trials/registries

Examples: - >50% stenosis used as clinically significant in multiple protocols/cohort selection. (bhailis2024improvingoutcomesin pages 2-3, NCT06822205 chunk 1) - ≥70% stenosis used as “high-grade” inclusion in multiple trial records. (NCT01208714 chunk 3, NCT05603221 chunk 1) - CORAL required stenosis ≥60% and enrolled high-grade lesions; subgroup definitions included >80%. (cooper2014stentingandmedical pages 8-9)

11. Outcome / prognosis

11.1 ARVD (trial and cohort outcomes)

Randomized trial evidence (CORAL) - CORAL randomized 947 patients to stenting+medical therapy vs medical therapy alone and found no difference in the primary composite endpoint: 35.1% vs 35.8% (HR 0.94, 95% CI 0.76–1.17; P=0.58) over median 43 months; systolic BP was modestly lower in the stent group (−2.3 mmHg). (cooper2014stentingandmedical pages 1-2)

Real-world phenotype-targeted outcomes (2024 MDT cohort) - Among revascularized patients, phenotype-specific improvements were reported: BP improvement in severe hypertension, attenuation of GFR decline in ischemic nephropathy, and no further HF admissions in heart-failure syndrome subgroup. (bhailis2024improvingoutcomesin pages 10-11)

Prognostic factors / predictors - Factors indicating lower benefit: atrophic kidney (length <8 cm) and significant proteinuria/albuminuria indicating irreversible parenchymal damage. (bhailis2024improvingoutcomesin pages 2-3) - Natural-history risk factors for progression/worse outcomes include high-grade stenosis, severe systolic hypertension, diabetes, abnormal baseline creatinine, and bilateral disease. (kumar2010naturalhistoryand pages 4-5)

11.2 Renal infarction outcomes (COVID-era case systematic review)

35 cases were included; 5 deaths occurred; renal function preserved in 17; renal impairment in 5; kidney replacement therapy in 5; invasive therapies performed in 2. (richer2020anovelrecurrent pages 8-9)

12. Treatment

12.1 Medical therapy (ARVD)

Standard of care includes multifactorial cardiovascular risk reduction: antihypertensive, antiplatelet, and lipid-lowering agents, with diabetes optimization when relevant. (pappaccogli2023endovascularversusmedical pages 1-5)

12.2 Revascularization (ARVD): evidence base and indications

Evidence (CORAL) - No reduction in major renal/cardiovascular outcomes with routine stenting in addition to optimized medical therapy; small BP difference. (cooper2014stentingandmedical pages 1-2)

Guideline-oriented selection (2023 ESH as summarized in 2024 CKJ review) - Atherosclerotic renovascular disease: offer revascularization in addition to medical therapy for patients with documented secondary hypertension from ARVD or high-risk clinical presentations such as flash pulmonary edema, refractory hypertension, or rapid loss of kidney function, when stenosis is high-grade (≥70%). (theodorakopoulou2024guidelinesforthe pages 10-11) - FMD and critical renal artery stenosis: recommended balloon angioplasty without stenting. (theodorakopoulou2024guidelinesforthe pages 10-11)

Implementation/real-world practice (MDT cohort) - Multidisciplinary review selected patients based on clinical phenotype, lesion severity, and downstream kidney state; 79% had presentation-specific benefit after revascularization in their retrospective series. (bhailis2024improvingoutcomesin pages 1-2)

12.3 Renal infarction (acute occlusion)

Conservative therapy dominated, with low molecular weight heparin common, and a minority receiving thrombus aspiration or catheter-directed thrombolysis; authors conclude conservative measures often suffice but severe cases may need aggressive therapy. (richer2020anovelrecurrent pages 8-9)

12.4 MAXO term suggestions (treatments/actions)

Percutaneous transluminal angioplasty (renal) (MAXO: term not retrieved; suggested)
Renal artery stent placement (MAXO suggested)
Antihypertensive therapy (MAXO suggested)
Antiplatelet therapy (MAXO suggested)
Lipid-lowering therapy (MAXO suggested)
Anticoagulation therapy (MAXO suggested)
Thrombolytic therapy (MAXO suggested)

12.5 Ongoing/registered clinical studies (examples)

METRAS (Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis), NCT01208714: randomized PTRAS vs optimal medical treatment with long-term follow-up and eligibility based on angio-CT stenosis thresholds and Doppler resistance index criteria. (NCT01208714 chunk 3)
European/International FMD Registry and Initiative, NCT04804683: recruiting registry/initiative (interventional designation in record). (ClinicalTrials.gov record retrieved; see trial list) (NCT01208714 chunk 3)

13. Prevention

No RAO-specific primary prevention interventions were detailed in retrieved sources beyond general atherosclerotic cardiovascular risk-factor control inherent to ARVD management (lipids, BP, antiplatelet where indicated). (pappaccogli2023endovascularversusmedical pages 1-5)

14. Other species / natural disease

No naturally occurring veterinary disease evidence for renal artery obstruction was identified in the retrieved evidence.

15. Model organisms

No animal or in vitro model organism data were identified in the retrieved evidence set.

Key recent developments (2023–2024 emphasis)

1) Refined patient selection for revascularization - 2024 MDT cohort emphasizes that outcomes depend on clinical presentation and downstream kidney state, reporting high proportions of phenotype-specific improvement after revascularization when selected by MDT review. (bhailis2024improvingoutcomesin pages 1-2, bhailis2024improvingoutcomesin pages 10-11)

2) Guideline clarification for high-risk ARVD - The 2024 CKJ guideline review of 2023 ESH guidance supports revascularization for high-risk phenotypes with ≥70% stenosis and recommends angioplasty without stenting for FMD. (theodorakopoulou2024guidelinesforthe pages 10-11)

3) Emerging diagnostics and “renal penumbra” concept - The 2023 Hypertension review highlights functional imaging (e.g., BOLD-MRI) to distinguish salvageable post-stenotic kidney (“renal penumbra”), and lists candidate biomarkers (NGAL, FGF-23) and novel therapeutic adjuncts (cell/growth factor approaches). (pappaccogli2023endovascularversusmedical pages 15-20, pappaccogli2023endovascularversusmedical pages 32-35)

Evidence map table

The following table compacts etiologies, clinical syndromes, diagnostics, and outcomes with key statistics.

Etiologic subtype	Typical patient profile / risk factors	Hallmark clinical presentations / phenotypes	Key diagnostics and thresholds	Key quantitative data	Key evidence (year, journal, PMID/DOI, URL)
Atherosclerotic renovascular disease (ARVD) / atherosclerotic renal artery stenosis	Usually older adults; prevalence rises with age; enriched in end-stage CKD, coronary artery disease, heart failure; generalized atherosclerosis; resistant/secondary hypertension risk context (pappaccogli2023endovascularversusmedical pages 1-5, NCT00885768 chunk 1)	Asymptomatic disease to renovascular hypertension, malignant/resistant hypertension, recurrent flash pulmonary edema, rapidly progressive CKD, AKI; may present with heart-failure syndromes (“Pickering syndrome”) (pappaccogli2023endovascularversusmedical pages 1-5, pappaccogli2023endovascularversusmedical pages 12-15)	MeSH term: Renal Artery Obstruction (D012078); angiography gold standard; trial/registry thresholds commonly >50%, ≥60%, ≥70%, ≥80%; CORAL enrolled stenosis ≥60%; METRAS: >70% on angio-CT or <70% with post-stenotic dilatation plus Doppler RI criteria; high-risk revascularization guideline phenotype: high-grade stenosis ≥70% with flash pulmonary edema, refractory hypertension, or rapid renal decline (NCT00885768 chunk 1, NCT01208714 chunk 3, cooper2014stentingandmedical pages 1-2, theodorakopoulou2024guidelinesforthe pages 10-11)	Prevalence: ~1–2% of all hypertension; ~7% of adults >65 have RAS >60%; 10–12% in ESRD; 15–30% with CAD; up to 50% in heart failure. Natural history: progression in 44% over mean 52 months; 16% to total occlusion; occlusion 39% in 75–99% stenosis vs 5% in <50% group. CORAL: primary composite events 35.1% stent+medical vs 35.8% medical only, HR 0.94 (95% CI 0.76–1.17), median follow-up 43 months; SBP difference −2.3 mmHg favoring stent (pappaccogli2023endovascularversusmedical pages 1-5, kumar2010naturalhistoryand pages 2-2, cooper2014stentingandmedical pages 1-2)	Pappaccogli et al., 2023, Hypertension, DOI: 10.1161/HYPERTENSIONAHA.122.17965, https://doi.org/10.1161/HYPERTENSIONAHA.122.17965; Cooper et al., 2014, N Engl J Med, DOI: 10.1056/NEJMoa1310753, https://doi.org/10.1056/NEJMoa1310753; Kumar et al., 2010, Nephrology, DOI: 10.1111/j.1440-1797.2009.01242.x, https://doi.org/10.1111/j.1440-1797.2009.01242.x (pappaccogli2023endovascularversusmedical pages 1-5, cooper2014stentingandmedical pages 1-2, kumar2010naturalhistoryand pages 2-2)
Fibromuscular dysplasia (FMD)-related renal artery stenosis	More typical in younger patients, especially women; nonatherosclerotic, noninflammatory arteriopathy; can be multifocal (“string-of-beads”); associated systemic arteriopathy/dissection burden; pediatric FMD may differ from adult FMD (theodorakopoulou2024guidelinesforthe pages 10-11, pytlos2024renalarterystenosis pages 1-2)	Renovascular/resistant hypertension, renal artery stenosis, occasionally renal infarction; multifocal disease, dissections, aneurysms; characteristic angiographic “string-of-beads” in adults; may coexist with cerebrovascular/cervical lesions (theodorakopoulou2024guidelinesforthe pages 10-11, pytlos2024renalarterystenosis pages 1-2)	ESH 2023/2024 synopsis: for FMD and critical RAS, balloon angioplasty without stenting; brain-to-pelvis imaging and antiplatelet therapy discussed in 2024 review; diagnosis/classification relies on angiographic features after excluding mimics (theodorakopoulou2024guidelinesforthe pages 10-11)	Evidence in chat is mainly qualitative; case-report summary notes angioplasty may alleviate hypertension in up to 80% of cases; pediatric review emphasizes heterogeneity and under-recognition rather than firm prevalence for adult renal FMD (pytlos2024renalarterystenosis pages 1-2)	Theodorakopoulou et al., 2024, Clin Kidney J, DOI: 10.1093/ckj/sfae278, https://doi.org/10.1093/ckj/sfae278; Pytlos et al., 2024, J Clin Med, DOI: 10.3390/jcm13226778, https://doi.org/10.3390/jcm13226778; Østergaard et al., 2024, J Clin Hypertens, DOI: 10.1111/jch.14865, https://doi.org/10.1111/jch.14865 (theodorakopoulou2024guidelinesforthe pages 10-11, pytlos2024renalarterystenosis pages 1-2)
Acute renal artery thrombosis / embolism / renal infarction	Often linked to cardioembolic disease (especially atrial fibrillation), thrombosis, hypercoagulable states, aortic dissection, trauma or iatrogenic injury; COVID-19-associated thrombosis reported; can also occur with FMD (pappaccogli2023endovascularversusmedical pages 1-5, richer2020anovelrecurrent pages 8-9)	Acute flank/abdominal pain, nausea/vomiting, fever, hematuria, hypertension, AKI; can be misdiagnosed as nephrolithiasis or appendicitis; some asymptomatic incidental cases reported; bilateral occlusion may cause severe kidney failure/anuria (richer2020anovelrecurrent pages 8-9)	Contrast-enhanced CT is repeatedly described as the key/gold-standard imaging modality; lab clues include elevated LDH, inflammatory markers, hematuria; DSA/CTA may define occlusion and guide thrombolysis/thrombectomy; inclusion studies distinguish high-grade stenosis from complete occlusion (NCT05603221 chunk 1, richer2020anovelrecurrent pages 8-9)	COVID-era systematic review: 35 cases in 33 reports; diagnosed within 1 month of SARS-CoV-2 in most cases; laterality right 7, left 15, bilateral 8, allograft 5; 17/35 had extrarenal thromboembolism; kidney replacement therapy in 5; invasive aspiration/thrombolysis in 2; 5 deaths; total renal function preserved in 17, renal impairment in 5. Renal infarction is symptomatic in >95% in one 2023 case review (richer2020anovelrecurrent pages 8-9)	Kozyrakis et al., 2023, Arch Ital Urol Androl, DOI: 10.4081/aiua.2023.11625, https://doi.org/10.4081/aiua.2023.11625; Mizusugi & Kenzaka, 2023, Medicina, DOI: 10.3390/medicina59061176, https://doi.org/10.3390/medicina59061176 (richer2020anovelrecurrent pages 8-9)
Pediatric renal artery stenosis / pediatric renovascular disease	Children with secondary hypertension; etiologies differ from adults and include FMD, mid-aortic syndrome (MAS), Takayasu arteritis, Kawasaki disease, segmental arterial mediolysis, neurofibromatosis type 1, renal artery aneurysm, trauma, radiation, tumor compression (pytlos2024renalarterystenosis pages 1-2)	Under-recognized cause of pediatric hypertension; can present with severe/refractory hypertension and target-organ damage; combined renal-artery and aortic narrowing in MAS; pharmacotherapy often partial only (pytlos2024renalarterystenosis pages 1-2)	Advanced imaging emphasized; Doppler velocity thresholds vary with age/size/circulatory state; multidisciplinary evaluation recommended; interventions include angioplasty, renal artery reimplantation, aorto-aortic bypass depending on pathology/extent (pytlos2024renalarterystenosis pages 1-2)	Pediatric arterial hypertension prevalence ~4%; renovascular disease causes 5–10% of secondary hypertension in children; MAS accounts for 0.5–2% of aortic stenosis; 20–48% of children with renovascular hypertension may have combined renal artery and mid-aortic narrowing (pytlos2024renalarterystenosis pages 1-2)	Pytlos et al., 2024, J Clin Med, DOI: 10.3390/jcm13226778, https://doi.org/10.3390/jcm13226778 (pytlos2024renalarterystenosis pages 1-2)
High-risk ARVD subgroup likely to benefit from revascularization	Patients selected by multidisciplinary review; anatomically significant stenosis with adequately sized kidney and one of: uncontrollable hypertension, deteriorating kidney function, or heart-failure syndrome; exclusion of atrophic/nonviable kidneys improves yield (pappaccogli2023endovascularversusmedical pages 12-15, richer2020anovelrecurrent pages 12-13)	Severe hypertension, progressive ischemic nephropathy, recurrent heart-failure admissions/flash pulmonary edema, ACEi/ARB-associated acute GFR fall (esp. bilateral disease/solitary kidney) (pappaccogli2023endovascularversusmedical pages 12-15, richer2020anovelrecurrent pages 12-13)	Predictors of limited benefit: kidney length <8 cm, cortical thickness <0.5 cm, renal resistive index >0.8, proteinuria >1 g/day; MDT series used stenosis ≥50% for review and international-guideline-based selection for revascularization (pappaccogli2023endovascularversusmedical pages 12-15, richer2020anovelrecurrent pages 12-13)	In 2024 MDT retrospective cohort, 127 patients with stenosis ≥50% were reviewed and 57 revascularized; 79% had presentation-specific benefit; BP improved in 82% with severe hypertension; 72% with progressive ischemic nephropathy had attenuated GFR decline; no further HF admissions in heart-failure subgroup; among those revascularized for high-grade stenosis alone, 78% had better BP control and 55% renal functional benefit (richer2020anovelrecurrent pages 12-13)	de Bhailis et al., 2024, J Nephrol, DOI: 10.1007/s40620-024-01902-1, https://doi.org/10.1007/s40620-024-01902-1; Pappaccogli et al., 2023, Hypertension, DOI: 10.1161/HYPERTENSIONAHA.122.17965, https://doi.org/10.1161/HYPERTENSIONAHA.122.17965 (richer2020anovelrecurrent pages 12-13, pappaccogli2023endovascularversusmedical pages 12-15)

Table: This table compacts the major clinical subtypes of renal artery obstruction and compares their risk factors, phenotypes, diagnostic thresholds, and quantitative evidence. It is useful as a quick-reference evidence map linking etiologic subtype to presentation, workup, and outcomes.

Visual evidence (diagnostic/decision algorithms)

Pappaccogli et al. (Hypertension 2023) include a decisional algorithm and a table summarizing diagnostic tests and novel strategies for ARVD management (Table 2 and Figure 3). These were retrieved as cropped images. (pappaccogli2023endovascularversusmedical media 2c3b7fe8, pappaccogli2023endovascularversusmedical media affaa2a8)

Important limitations / data not retrieved in this run

ICD-10/ICD-11, Orphanet, and MONDO identifiers for “renal artery obstruction” were not retrieved from the current evidence set and should be added via dedicated ontology lookup.
High-resolution incidence/prevalence estimates for adult renal infarction outside case series, and robust population statistics for renal FMD, were not retrieved.
Multi-omics (transcriptomics/proteomics/metabolomics), epigenetic signatures, and validated model-organism systems for RAO were not present in the retrieved texts.

References

(cooper2014stentingandmedical pages 1-2): Christopher J. Cooper, Timothy P. Murphy, Donald E. Cutlip, Kenneth Jamerson, William Henrich, Diane M. Reid, David J. Cohen, Alan H. Matsumoto, Michael Steffes, Michael R. Jaff, Martin R. Prince, Eldrin F. Lewis, Katherine R. Tuttle, Joseph I. Shapiro, John H. Rundback, Joseph M. Massaro, Ralph B. D'Agostino, and Lance D. Dworkin. Stenting and medical therapy for atherosclerotic renal-artery stenosis. The New England journal of medicine, 370 1:13-22, Jan 2014. URL: https://doi.org/10.1056/nejmoa1310753, doi:10.1056/nejmoa1310753. This article has 1274 citations and is from a highest quality peer-reviewed journal.
(theodorakopoulou2024guidelinesforthe pages 10-11): Marieta Theodorakopoulou, Alberto Ortiz, Beatriz Fernandez-Fernandez, Mehmet Kanbay, Roberto Minutolo, and Pantelis A Sarafidis. Guidelines for the management of hypertension in ckd patients: where do we stand in 2024? Clinical Kidney Journal, 17:ii36-ii50, Nov 2024. URL: https://doi.org/10.1093/ckj/sfae278, doi:10.1093/ckj/sfae278. This article has 41 citations and is from a peer-reviewed journal.
(bhailis2024improvingoutcomesin pages 10-11): Áine M. de Bhailis, Edward Lake, Constantina Chrysochou, Darren Green, Rajkumar Chinnadurai, and Philip A. Kalra. Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review. Journal of Nephrology, 37:1093-1105, Apr 2024. URL: https://doi.org/10.1007/s40620-024-01902-1, doi:10.1007/s40620-024-01902-1. This article has 7 citations and is from a peer-reviewed journal.
(pappaccogli2023endovascularversusmedical pages 1-5): Marco Pappaccogli, Tom Robberechts, Jean-Philippe Lengelé, Patricia Van der Niepen, Pantelis Sarafidis, Franco Rabbia, and Alexandre Persu. Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension, 80:1150-1161, Jun 2023. URL: https://doi.org/10.1161/hypertensionaha.122.17965, doi:10.1161/hypertensionaha.122.17965. This article has 38 citations and is from a domain leading peer-reviewed journal.
(kumar2010naturalhistoryand pages 2-2): Subramanian Karthik Kumar, Robert MacGinley, Murty Mantha, Peter Mount, Matthew Roberts, and George Mangos. Natural history and progression of atherosclerotic renal vascular stenosis. Nephrology, Apr 2010. URL: https://doi.org/10.1111/j.1440-1797.2009.01242.x, doi:10.1111/j.1440-1797.2009.01242.x. This article has 4 citations and is from a peer-reviewed journal.
(NCT00885768 chunk 1): Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization. Imam Khomeini Hospital. 2008. ClinicalTrials.gov Identifier: NCT00885768
(NCT01208714 chunk 3): Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study). University Hospital Padova. 2010. ClinicalTrials.gov Identifier: NCT01208714
(pytlos2024renalarterystenosis pages 1-2): Jakub Pytlos, Aneta Michalczewska, Piotr Majcher, Mariusz Furmanek, and Piotr Skrzypczyk. Renal artery stenosis and mid-aortic syndrome in children—a review. Journal of Clinical Medicine, 13:6778, Nov 2024. URL: https://doi.org/10.3390/jcm13226778, doi:10.3390/jcm13226778. This article has 6 citations.
(richer2020anovelrecurrent pages 8-9): Julie Richer, Hannah L. Hill, Yu Wang, Min-Lee Yang, Kristina L. Hunker, Jamie Lane, Susan Blackburn, Dawn M. Coleman, Jonathan Eliason, Guillaume Sillon, Maria-Daniela D’Agostino, Prasad Jetty, François-Pierre Mongeon, Anne-Marie Laberge, Stephen E. Ryan, Natalia Fendrikova-Mahlay, Thais Coutinho, Michael R. Mathis, Matthew Zawistowski, Stanley L. Hazen, Alexander E. Katz, Heather L. Gornik, Chad M. Brummett, Goncalo Abecasis, Ingrid L. Bergin, James C. Stanley, Jun Z. Li, and Santhi K. Ganesh. A novel recurrent col5a1 genetic variant is associated with a dysplasia-associated arterial disease exhibiting dissections and fibromuscular dysplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 40:2686-2699, Nov 2020. URL: https://doi.org/10.1161/atvbaha.119.313885, doi:10.1161/atvbaha.119.313885. This article has 50 citations and is from a domain leading peer-reviewed journal.
(kumar2010naturalhistoryand pages 4-5): Subramanian Karthik Kumar, Robert MacGinley, Murty Mantha, Peter Mount, Matthew Roberts, and George Mangos. Natural history and progression of atherosclerotic renal vascular stenosis. Nephrology, Apr 2010. URL: https://doi.org/10.1111/j.1440-1797.2009.01242.x, doi:10.1111/j.1440-1797.2009.01242.x. This article has 4 citations and is from a peer-reviewed journal.
(bhailis2024improvingoutcomesin pages 2-3): Áine M. de Bhailis, Edward Lake, Constantina Chrysochou, Darren Green, Rajkumar Chinnadurai, and Philip A. Kalra. Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review. Journal of Nephrology, 37:1093-1105, Apr 2024. URL: https://doi.org/10.1007/s40620-024-01902-1, doi:10.1007/s40620-024-01902-1. This article has 7 citations and is from a peer-reviewed journal.
(bhailis2024improvingoutcomesin pages 1-2): Áine M. de Bhailis, Edward Lake, Constantina Chrysochou, Darren Green, Rajkumar Chinnadurai, and Philip A. Kalra. Improving outcomes in atherosclerotic renovascular disease: importance of clinical presentation and multi-disciplinary review. Journal of Nephrology, 37:1093-1105, Apr 2024. URL: https://doi.org/10.1007/s40620-024-01902-1, doi:10.1007/s40620-024-01902-1. This article has 7 citations and is from a peer-reviewed journal.
(richer2020anovelrecurrent pages 1-2): Julie Richer, Hannah L. Hill, Yu Wang, Min-Lee Yang, Kristina L. Hunker, Jamie Lane, Susan Blackburn, Dawn M. Coleman, Jonathan Eliason, Guillaume Sillon, Maria-Daniela D’Agostino, Prasad Jetty, François-Pierre Mongeon, Anne-Marie Laberge, Stephen E. Ryan, Natalia Fendrikova-Mahlay, Thais Coutinho, Michael R. Mathis, Matthew Zawistowski, Stanley L. Hazen, Alexander E. Katz, Heather L. Gornik, Chad M. Brummett, Goncalo Abecasis, Ingrid L. Bergin, James C. Stanley, Jun Z. Li, and Santhi K. Ganesh. A novel recurrent col5a1 genetic variant is associated with a dysplasia-associated arterial disease exhibiting dissections and fibromuscular dysplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 40:2686-2699, Nov 2020. URL: https://doi.org/10.1161/atvbaha.119.313885, doi:10.1161/atvbaha.119.313885. This article has 50 citations and is from a domain leading peer-reviewed journal.
(richer2020anovelrecurrent pages 5-7): Julie Richer, Hannah L. Hill, Yu Wang, Min-Lee Yang, Kristina L. Hunker, Jamie Lane, Susan Blackburn, Dawn M. Coleman, Jonathan Eliason, Guillaume Sillon, Maria-Daniela D’Agostino, Prasad Jetty, François-Pierre Mongeon, Anne-Marie Laberge, Stephen E. Ryan, Natalia Fendrikova-Mahlay, Thais Coutinho, Michael R. Mathis, Matthew Zawistowski, Stanley L. Hazen, Alexander E. Katz, Heather L. Gornik, Chad M. Brummett, Goncalo Abecasis, Ingrid L. Bergin, James C. Stanley, Jun Z. Li, and Santhi K. Ganesh. A novel recurrent col5a1 genetic variant is associated with a dysplasia-associated arterial disease exhibiting dissections and fibromuscular dysplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 40:2686-2699, Nov 2020. URL: https://doi.org/10.1161/atvbaha.119.313885, doi:10.1161/atvbaha.119.313885. This article has 50 citations and is from a domain leading peer-reviewed journal.
(pappaccogli2023endovascularversusmedical pages 15-20): Marco Pappaccogli, Tom Robberechts, Jean-Philippe Lengelé, Patricia Van der Niepen, Pantelis Sarafidis, Franco Rabbia, and Alexandre Persu. Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension, 80:1150-1161, Jun 2023. URL: https://doi.org/10.1161/hypertensionaha.122.17965, doi:10.1161/hypertensionaha.122.17965. This article has 38 citations and is from a domain leading peer-reviewed journal.
(pappaccogli2023endovascularversusmedical pages 32-35): Marco Pappaccogli, Tom Robberechts, Jean-Philippe Lengelé, Patricia Van der Niepen, Pantelis Sarafidis, Franco Rabbia, and Alexandre Persu. Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension, 80:1150-1161, Jun 2023. URL: https://doi.org/10.1161/hypertensionaha.122.17965, doi:10.1161/hypertensionaha.122.17965. This article has 38 citations and is from a domain leading peer-reviewed journal.
(richer2020anovelrecurrent pages 7-8): Julie Richer, Hannah L. Hill, Yu Wang, Min-Lee Yang, Kristina L. Hunker, Jamie Lane, Susan Blackburn, Dawn M. Coleman, Jonathan Eliason, Guillaume Sillon, Maria-Daniela D’Agostino, Prasad Jetty, François-Pierre Mongeon, Anne-Marie Laberge, Stephen E. Ryan, Natalia Fendrikova-Mahlay, Thais Coutinho, Michael R. Mathis, Matthew Zawistowski, Stanley L. Hazen, Alexander E. Katz, Heather L. Gornik, Chad M. Brummett, Goncalo Abecasis, Ingrid L. Bergin, James C. Stanley, Jun Z. Li, and Santhi K. Ganesh. A novel recurrent col5a1 genetic variant is associated with a dysplasia-associated arterial disease exhibiting dissections and fibromuscular dysplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 40:2686-2699, Nov 2020. URL: https://doi.org/10.1161/atvbaha.119.313885, doi:10.1161/atvbaha.119.313885. This article has 50 citations and is from a domain leading peer-reviewed journal.
(piechocki2024…peripheral pages 13-15): M Piechocki, T Przewłocki, and P Pieniążek. … , peripheral arterial atherosclerotic disease (carotid, renal, lower limb) in elderly patients—a review: part i—epidemiology, risk factors, and atherosclerosis …. Unknown journal, 2024.
(NCT06822205 chunk 1): Identification and Treatment of Renal Stenosis in Transplanted Kidneys. IRCCS Azienda Ospedaliero-Universitaria di Bologna. 2023. ClinicalTrials.gov Identifier: NCT06822205
(NCT05603221 chunk 1): Renal Perfusion Assessment in the Endovascular Treatment of Renal Artery Stenosis. Peking Union Medical College Hospital. 2020. ClinicalTrials.gov Identifier: NCT05603221
(cooper2014stentingandmedical pages 8-9): Christopher J. Cooper, Timothy P. Murphy, Donald E. Cutlip, Kenneth Jamerson, William Henrich, Diane M. Reid, David J. Cohen, Alan H. Matsumoto, Michael Steffes, Michael R. Jaff, Martin R. Prince, Eldrin F. Lewis, Katherine R. Tuttle, Joseph I. Shapiro, John H. Rundback, Joseph M. Massaro, Ralph B. D'Agostino, and Lance D. Dworkin. Stenting and medical therapy for atherosclerotic renal-artery stenosis. The New England journal of medicine, 370 1:13-22, Jan 2014. URL: https://doi.org/10.1056/nejmoa1310753, doi:10.1056/nejmoa1310753. This article has 1274 citations and is from a highest quality peer-reviewed journal.
(pappaccogli2023endovascularversusmedical pages 12-15): Marco Pappaccogli, Tom Robberechts, Jean-Philippe Lengelé, Patricia Van der Niepen, Pantelis Sarafidis, Franco Rabbia, and Alexandre Persu. Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension, 80:1150-1161, Jun 2023. URL: https://doi.org/10.1161/hypertensionaha.122.17965, doi:10.1161/hypertensionaha.122.17965. This article has 38 citations and is from a domain leading peer-reviewed journal.
(richer2020anovelrecurrent pages 12-13): Julie Richer, Hannah L. Hill, Yu Wang, Min-Lee Yang, Kristina L. Hunker, Jamie Lane, Susan Blackburn, Dawn M. Coleman, Jonathan Eliason, Guillaume Sillon, Maria-Daniela D’Agostino, Prasad Jetty, François-Pierre Mongeon, Anne-Marie Laberge, Stephen E. Ryan, Natalia Fendrikova-Mahlay, Thais Coutinho, Michael R. Mathis, Matthew Zawistowski, Stanley L. Hazen, Alexander E. Katz, Heather L. Gornik, Chad M. Brummett, Goncalo Abecasis, Ingrid L. Bergin, James C. Stanley, Jun Z. Li, and Santhi K. Ganesh. A novel recurrent col5a1 genetic variant is associated with a dysplasia-associated arterial disease exhibiting dissections and fibromuscular dysplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 40:2686-2699, Nov 2020. URL: https://doi.org/10.1161/atvbaha.119.313885, doi:10.1161/atvbaha.119.313885. This article has 50 citations and is from a domain leading peer-reviewed journal.
(pappaccogli2023endovascularversusmedical media 2c3b7fe8): Marco Pappaccogli, Tom Robberechts, Jean-Philippe Lengelé, Patricia Van der Niepen, Pantelis Sarafidis, Franco Rabbia, and Alexandre Persu. Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension, 80:1150-1161, Jun 2023. URL: https://doi.org/10.1161/hypertensionaha.122.17965, doi:10.1161/hypertensionaha.122.17965. This article has 38 citations and is from a domain leading peer-reviewed journal.
(pappaccogli2023endovascularversusmedical media affaa2a8): Marco Pappaccogli, Tom Robberechts, Jean-Philippe Lengelé, Patricia Van der Niepen, Pantelis Sarafidis, Franco Rabbia, and Alexandre Persu. Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension, 80:1150-1161, Jun 2023. URL: https://doi.org/10.1161/hypertensionaha.122.17965, doi:10.1161/hypertensionaha.122.17965. This article has 38 citations and is from a domain leading peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Pathophysiology

Pathograph

Phenotypes

Treatments

Environmental Factors

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive Research Report: Renal Artery Obstruction (Renal Artery Obstruction / Renal Artery Stenosis / Renal Artery Occlusion)

Executive summary (current understanding)

1. Disease information

1.1 Definition and scope

1.2 Key identifiers and ontology mappings

1.3 Synonyms and alternative names (as used in evidence)

1.4 Evidence source types

2. Etiology

2.1 Disease causal factors (primary causes)

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical presentation)

3.1 Core phenotypes for ARVD / chronic RAO

3.2 Phenotypes for acute renal artery occlusion / renal infarction

3.3 Pediatric renovascular disease phenotypes

4. Genetic / molecular information

4.1 Causal genes

4.2 Pathogenic variants and variant details (FMD-spectrum)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

6.1 ARVD causal chain (hemodynamic ischemia → kidney dysfunction and systemic effects)

6.2 FMD-spectrum vascular wall pathology

6.3 GO / CL term suggestions (mechanism-linked)

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

9.1 Epidemiology (selected quantitative data)

9.2 Natural history/progression (ARVD)

9.3 Genetic etiology population notes

10. Diagnostics

10.1 Clinical tests and biomarkers

10.2 Imaging

10.3 Functional/advanced diagnostics (emerging)

10.4 Diagnostic thresholds used in trials/registries

11. Outcome / prognosis

11.1 ARVD (trial and cohort outcomes)

11.2 Renal infarction outcomes (COVID-era case systematic review)

12. Treatment

12.1 Medical therapy (ARVD)

12.2 Revascularization (ARVD): evidence base and indications

12.3 Renal infarction (acute occlusion)

12.4 MAXO term suggestions (treatments/actions)

12.5 Ongoing/registered clinical studies (examples)

13. Prevention

14. Other species / natural disease

15. Model organisms